NYLI Epoch Capital Growth Investor Class holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
NYLI Epoch Capital Growth Investor Class MECVX
- NAV / 1-Day Return 16.10 / −2.60 %
- Total Assets 133.5M
-
Adj. Expense Ratio
1.420%
- Expense Ratio 1.420%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Global Large-Stock Growth
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 33%
USD | NAV as of Jun 06, 2026 | 1-Day Return as of Jun 06, 2026, 12:49 AM GMT+0
Morningstar’s Analysis MECVX
Will MECVX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the MECVX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of MECVX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 20.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
NVIDIA Corp | 3.46 | 5M | Technology |
Apple Inc | 2.29 | 3M | Technology |
EMCOR Group Inc | 2.12 | 3M | Industrials |
Fabrinet | 2.10 | 3M | Technology |
Alphabet Inc Class A | 1.97 | 3M | Communication Services |
Broadcom Inc | 1.90 | 3M | Technology |
Hoya Corp | 1.78 | 2M | Healthcare |
Taiwan Semiconductor Manufacturing Co Ltd | 1.66 | 2M | Technology |
AbbVie Inc | 1.57 | 2M | Healthcare |
West Pharmaceutical Services Inc | 1.54 | 2M | Healthcare |
United States